LOS ANGELES , Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI ) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024.
These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company focused on the commercialization of FYARRO ® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact: [email protected] SOURCE Aadi Bioscience.
